<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>Pfizer AB - pressmeddelanden</title>
    <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/list</link>
    <description>Mynewsdesk nyhetsfeed direkt fr&#229;n k&#228;llan</description>
    <image>
      <title>Pfizer AB - pressmeddelanden</title>
      <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/list</link>
      <url>http://www.mynewsdesk.com/images/redesign/graphics/logos/logo-small.png</url>
      <width>128</width>
      <height>23</height>
    </image>
    <language>sv</language>
    <ttl>15</ttl>
<item>
  <title>V&#228;stra G&#246;talandsregionen valde pneumokockvaccinet Prevenar 13</title>
  <pubDate>Wed, 18 Jan 2012 08:00:00 +0100</pubDate>
  <description>Landstinget i V&#228;stra G&#246;talandsregionen har nyligen avslutat en upphandling av pneumokockvaccin. Medicinsk &#228;ndam&#229;lsenlighet talade f&#246;r pneumokockvaccinet Prevenar 13, som &#228;r det enda barnvaccinet som ger skydd mot tretton varianter av pneumokockbakterien, inklusive pneumokocktypen 19A.</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/vaestra-goetalandsregionen-valde-pneumokockvaccinet-prevenar-13-724413?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/vaestra-goetalandsregionen-valde-pneumokockvaccinet-prevenar-13-724413?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>L&#228;kemedel f&#246;r bl&#246;darsjuka nu tillg&#228;ngligt i f&#246;rpackning som kan f&#246;rvaras i rumstemperatur</title>
  <pubDate>Thu, 29 Dec 2011 11:02:56 +0100</pubDate>
  <description>Europeiska kommissionen har nyligen godk&#228;nt en produktutveckling av BeneFIX f&#246;r patienter med hemofili B (bl&#246;darsjuka) som betyder att medicinen inte l&#228;ngre beh&#246;ver kylf&#246;rvaras vilket medf&#246;r stora f&#246;rdelar f&#246;r patientens vardag. </description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/laekemedel-foer-bloedarsjuka-nu-tillgaengligt-i-foerpackning-som-kan-foervaras-i-rumstemperatur-719502?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/laekemedel-foer-bloedarsjuka-nu-tillgaengligt-i-foerpackning-som-kan-foervaras-i-rumstemperatur-719502?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>Lyrica kvarst&#229;r i h&#246;gkostnadsskyddet med begr&#228;nsningar</title>
  <pubDate>Thu, 22 Dec 2011 16:06:00 +0100</pubDate>
  <description>Tandv&#229;rds- och L&#228;kemedelsf&#246;rm&#229;nsverket, TLV, har fattat beslut som inneb&#228;r att l&#228;kemedlet Lyrica &#228;ven forts&#228;ttningsvis ska ing&#229; i h&#246;gkostnadsskyddet p&#229; tre olika omr&#229;den &#8211; epilepsi, generaliserat &#229;ngestsyndrom och nervsm&#228;rta.</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/lyrica-kvarstaar-i-hoegkostnadsskyddet-med-begraensningar-718569?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/lyrica-kvarstaar-i-hoegkostnadsskyddet-med-begraensningar-718569?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>Pregabalin kvarst&#229;r i h&#246;gkostnadsskyddet med begr&#228;nsningar</title>
  <pubDate>Tue, 20 Dec 2011 10:33:03 +0100</pubDate>
  <description>Nu har Tandv&#229;rds- och l&#228;kemedelsf&#246;rm&#229;nsverket, TLV, fattat beslut som inneb&#228;r att Lyrica (pregabalin) &#228;ven forts&#228;ttningsvis ska ing&#229; i h&#246;gkostnadsskyddet p&#229; tre olika omr&#229;den &#8211; epilepsi, neuropatisk sm&#228;rta, generaliserat &#229;ngestsyndrom. 
</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/pregabalin-kvarstaar-i-hoegkostnadsskyddet-med-begraensningar-717428?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/pregabalin-kvarstaar-i-hoegkostnadsskyddet-med-begraensningar-717428?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>V&#228;lbepr&#246;vat barnvaccin mot pneumokocker godk&#228;nt f&#246;r vuxna </title>
  <pubDate>Thu, 15 Dec 2011 09:00:00 +0100</pubDate>
  <description>EU-kommissionen har nu godk&#228;nt vaccinet Prevenar 13 f&#246;r f&#246;rebyggande av invasiv pneumokocksjukdom f&#246;r vuxna &#246;ver 50 &#229;rs &#229;lder. Prevenar 13 tillh&#246;r en ny generation pneumokockvaccin som har f&#246;ruts&#228;ttningar att ge ett l&#228;ngre och kraftigare skydd j&#228;mf&#246;rt med dagens standardvaccin. Prevenar 13 anv&#228;nds idag inom ramen f&#246;r det svenska barnvaccinationsprogrammet och &#228;r v&#228;l bepr&#246;vat.</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/vaelbeproevat-barnvaccin-mot-pneumokocker-godkaent-foer-vuxna-706632?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/vaelbeproevat-barnvaccin-mot-pneumokocker-godkaent-foer-vuxna-706632?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>TLV-beslut: Nytt oralt medel mot blodproppar inkluderas i l&#228;kemedelsf&#246;rm&#229;nen </title>
  <pubDate>Mon, 12 Dec 2011 09:00:00 +0100</pubDate>
  <description>Eliquis (apixaban) har f&#229;tt godk&#228;nt att ing&#229; i l&#228;kemedelsf&#246;rm&#229;nen enligt ett beslut av Tandv&#229;rds- och l&#228;kemedelsf&#246;rm&#229;nsverket (TLV), fredagen den 9 december. Eliquis, som &#228;r en tablett, har godk&#228;nts f&#246;r att f&#246;rebygga blodproppar hos personer som opererats f&#246;r att byta kn&#228;- eller h&#246;ftleder. </description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/tlv-beslut-nytt-oralt-medel-mot-blodproppar-inkluderas-i-laekemedelsfoermaanen-714331?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/tlv-beslut-nytt-oralt-medel-mot-blodproppar-inkluderas-i-laekemedelsfoermaanen-714331?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>L&#229;ngtidsdata bekr&#228;ftar att Xiapex &#228;r effektivt vid behandling av Dupuytrens kontraktur</title>
  <pubDate>Fri, 02 Dec 2011 09:10:00 +0100</pubDate>
  <description>Tre&#229;rsdata fr&#229;n en fas III-studien presenterades i september p&#229; den amerikanska handkirurgkongressen ASSH. Samma vecka redovisades &#228;ven en utv&#228;rdering som visar f&#246;rb&#228;ttrade behandlingsresultat fr&#229;n klinisk vardag j&#228;mf&#246;rt med resultaten i det kliniska pr&#246;vningsprogrammet. Dessa ger ytterligare st&#246;d f&#246;r att Xiapex &#228;r ett effektivt alternativ till operation vid sjukdomen Dupuytrens kontraktur.</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/laangtidsdata-bekraeftar-att-xiapex-aer-effektivt-vid-behandling-av-dupuytrens-kontraktur-711350?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/laangtidsdata-bekraeftar-att-xiapex-aer-effektivt-vid-behandling-av-dupuytrens-kontraktur-711350?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>Vilija Oke tilldelas Pfizerstipendiet 2011 f&#246;r yngre forskare</title>
  <pubDate>Wed, 30 Nov 2011 08:00:00 +0100</pubDate>
  <description>Pfizerstipendiet f&#246;r yngre forskare tilldelas i &#229;r Vilija Oke vid Karolinska Universitetssjukhuset. Hon bel&#246;nas f&#246;r sin lovande translationella forskning om vilken inverkan olika milj&#246;faktorer har p&#229; att huden drabbas vid reumatiska sjukdomar. </description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/vilija-oke-tilldelas-pfizerstipendiet-2011-foer-yngre-forskare-709188?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/vilija-oke-tilldelas-pfizerstipendiet-2011-foer-yngre-forskare-709188?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>St&#246;rsta stipendiet inom svensk reumatologisk forskning: Thomas Skogh tilldelas Pfizers stora forskningsstipendium</title>
  <pubDate>Mon, 28 Nov 2011 08:00:00 +0100</pubDate>
  <description>Professor Thomas Skogh vid Universitetssjukhuset i Link&#246;ping, tilldelas Pfizers stora forskningsstipendium 2011. Han bel&#246;nas f&#246;r sin innovativa och m&#229;linriktade forskning om antikroppar och deras kliniska betydelse vid ledg&#229;ngsreumatism och den reumatiska systemsjukdomen SLE. Forskningen har resulterat i b&#229;de nationell samt internationell uppm&#228;rksamhet.</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/thomas-skogh-tilldelas-pfizers-stora-forskningsstipendium-709181?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/thomas-skogh-tilldelas-pfizers-stora-forskningsstipendium-709181?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>EU godk&#228;nner Vyndaqel &#8211; nytt l&#228;kemedel f&#246;r behandling av transtyretinamyloidos</title>
  <pubDate>Mon, 21 Nov 2011 14:06:00 +0100</pubDate>
  <description>EU-kommissionen har nu godk&#228;nt Vyndaqel (tafamidis) som f&#246;rsta l&#228;kemedel att behandla transtyretinamyloidos (TTR-FAP) hos vuxna med symtomgivande polyneuropati i stadium 1, f&#246;r att f&#246;rdr&#246;ja perifer neurologisk f&#246;rs&#228;mring. TTR-FAP &#228;r en s&#228;llsynt, &#228;rftlig och progressiv sjukdom som ger symtom fr&#229;n bland annat perifera nerver, hj&#228;rta, mag-tarmkanal och njurar. </description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/eu-godkaenner-vyndaqel-nytt-laekemedel-foer-behandling-av-transtyretinamyloidos-707077?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/eu-godkaenner-vyndaqel-nytt-laekemedel-foer-behandling-av-transtyretinamyloidos-707077?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>KOL-testa dina lungor gratis</title>
  <pubDate>Mon, 14 Nov 2011 09:58:00 +0100</pubDate>
  <description>300 000 svenskar har den obotliga sjukdomen KOL utan att veta om det. Tidig diagnos &#228;r avg&#246;rande f&#246;r att kunna bevara en god livskvalitet. I samband med internationella KOL-dagen erbjuds gratis lungfunktionstest p&#229; flera orter runtom i landet.</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/kol-testa-dina-lungor-gratis-704038?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/kol-testa-dina-lungor-gratis-704038?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>Viagrarapporten 2011: Var fj&#228;rde man &#246;ver 50 &#229;r har problem med potensen</title>
  <pubDate>Thu, 29 Sep 2011 10:30:00 +0200</pubDate>
  <description>Idag presenteras &#8221;Viagrarapporten 2011&#8221;. Unders&#246;kningen inkluderar 2862 svenska m&#228;n och kvinnor som svarat p&#229; fr&#229;gor om sexuell h&#228;lsa, vanor och problem. Rapporten har genomf&#246;rts av Novus Opinion p&#229; uppdrag av l&#228;kemedelsf&#246;retaget Pfizer. Viagrarapporten visar att var fj&#228;rde man &#246;ver 50 &#229;r har erektionsproblem. Kvinnor i samma &#229;lder drabbas av minskad sexlust och sv&#229;righeter att bli upphetsade. 1</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/viagrarapporten-2011-var-fjaerde-man-oever-50-aar-har-problem-med-potensen-687190?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/viagrarapporten-2011-var-fjaerde-man-oever-50-aar-har-problem-med-potensen-687190?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>Kliniska data fr&#229;n Pfizers onkologiportf&#246;lj presenteras vid ECCO/ESMO-kongressen i Stockholm</title>
  <pubDate>Fri, 23 Sep 2011 12:15:00 +0200</pubDate>
  <description>I samband med den europeiska cancerkongressen ECCO/ESMO i Stockholm kommer Pfizer att presentera data som utv&#228;rderar crizotinib vid avancerad ALK-positiv icke-sm&#229;cellig lungcancer (NSCLC), data om axitinib fr&#229;n f&#246;retagets njurcancerportf&#246;lj (RCC) samt data om Sutent (sunitinib malat). Kongressen b&#246;rjar idag och p&#229;g&#229;r till den 27 september.

</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/kliniska-data-fraan-pfizers-onkologiportfoelj-presenteras-vid-ecco-esmo-kongressen-i-stockholm-685674?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/kliniska-data-fraan-pfizers-onkologiportfoelj-presenteras-vid-ecco-esmo-kongressen-i-stockholm-685674?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>Amerikanska FDA godk&#228;nner nytt l&#228;kemedel mot ALK-positiv icke-sm&#229;cellig lungcancer</title>
  <pubDate>Tue, 20 Sep 2011 09:15:00 +0200</pubDate>
  <description>FDA (Food and Drug Administration) har godk&#228;nt Xalkori (crizotinib) f&#246;r behandling av lokalt avancerad eller metastaserad ALK-positiv icke-sm&#229;cellig lungcancer (NSCLC), dvs tum&#246;rer som uttrycker en defekt ALK-gen. Ett diagnostiskt test anv&#228;nds f&#246;r att identifiera den defekta ALK-fusionsgenen.</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/amerikanska-fda-godkaenner-nytt-laekemedel-mot-alk-positiv-icke-smaacellig-lungcancer-683461?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/amerikanska-fda-godkaenner-nytt-laekemedel-mot-alk-positiv-icke-smaacellig-lungcancer-683461?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>Ny app g&#246;r det l&#228;tt att hitta toalett</title>
  <pubDate>Fri, 09 Sep 2011 08:00:00 +0200</pubDate>
  <description>Var &#228;r n&#228;rmaste offentliga toalett i Stockholm, G&#246;teborg och Malm&#246;? Det kan en ny app ge svar p&#229;. Sm&#229;barnsf&#246;r&#228;ldrar, personer med funktionsneds&#228;ttning, tillf&#228;lliga bes&#246;kare och storstadsbor f&#229;r med n&#229;gra enkla knapptryck hj&#228;lp att hitta l&#228;mplig toalett. </description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/ny-app-goer-det-laett-att-hitta-toalett-679382?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/ny-app-goer-det-laett-att-hitta-toalett-679382?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>J&#246;nk&#246;ping valde Prevenar 13 mot pneumokocker</title>
  <pubDate>Wed, 31 Aug 2011 08:15:18 +0200</pubDate>
  <description>Landstinget i J&#246;nk&#246;pings l&#228;n har nyligen avslutat en upphandling av barnvacciner. Medicinsk &#228;ndam&#229;lsenlighet talade f&#246;r pneumokockvaccinet Prevenar som &#228;r det enda barnvaccinet som ger skydd mot tretton varianter av pneumokockbakterien, inklusive bakterien 19A.</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/joenkoeping-valde-prevenar-13-mot-pneumokocker-675750?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/joenkoeping-valde-prevenar-13-mot-pneumokocker-675750?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>Eliquis (apixaban) effektivare &#228;n Waran - s&#228;nker risken f&#246;r stroke </title>
  <pubDate>Mon, 29 Aug 2011 11:39:00 +0200</pubDate>
  <description>Eliquis (apixaban) minskar risken f&#246;r stroke eller systemisk embolism med 21 procent j&#228;mf&#246;rt med standardbehandlingen Waran. Allvarliga bl&#246;dningar minskar med 31 procent och den totala d&#246;dligheten med 11 procent. Eliquis &#228;r det f&#246;rsta orala blodf&#246;rtunnande l&#228;kemedlet som signifikant minskar total d&#246;dlighet j&#228;mf&#246;rt med Waran. Detta visar fas III-studien Aristotle som presenterades i s&#246;ndags.</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/eliquis-apixaban-effektivare-aen-waran-saenker-risken-foer-stroke-674848?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/eliquis-apixaban-effektivare-aen-waran-saenker-risken-foer-stroke-674848?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>Filmpremi&#228;r p&#229; Potenslinjen.se: "Malena pratar potens"</title>
  <pubDate>Wed, 10 Aug 2011 07:30:00 +0200</pubDate>
  <description>I &#229;r &#228;r det 25 &#229;r sedan sexologen Malena Ivarsson gjorde debut i etern. M&#229;nga minns henne fr&#229;n teveserien &#8221;Fr&#228;cka fredag&#8221; d&#228;r svenskar fick l&#228;ra sig om sex p&#229; ett helt nytt s&#228;tt. Nu presenteras webbfilmen &#8221;Malena pratar potens&#8221; som &#228;r en blinkning till 80-talets program. Syftet &#228;r att bryta tabut kring erektionsproblem och f&#229; fler att s&#246;ka hj&#228;lp.</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/filmpremiaer-paa-potenslinjen-se-malena-pratar-potens-668457?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/filmpremiaer-paa-potenslinjen-se-malena-pratar-potens-668457?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>Pressinbjudan Almedalen: Regeringens l&#228;kemedelsstrategi &#8211; i v&#228;ntan p&#229; kejsarens nya kl&#228;der?</title>
  <pubDate>Thu, 23 Jun 2011 08:40:00 +0200</pubDate>
  <description>V&#228;lkommen till ett seminarium f&#246;r att ge klarhet kring vad vi kan v&#228;nta oss av regeringens nationella l&#228;kemedelsstrategi den 7 juli p&#229; Clarion Hotel Wisby.

</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/pressinbjudan-almedalen-regeringens-laekemedelsstrategi-i-vaentan-paa-kejsarens-nya-klaeder-654335?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/pressinbjudan-almedalen-regeringens-laekemedelsstrategi-i-vaentan-paa-kejsarens-nya-klaeder-654335?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
<item>
  <title>Pressinbjudan Almedalen: Valet 2014 &#8211; ett v&#229;rdval? </title>
  <pubDate>Thu, 23 Jun 2011 08:30:00 +0200</pubDate>
  <description>V&#228;lkommen till en debatt om valet 2014 &#8211; ett v&#229;rdval den 4 juli p&#229; Clarion Hotel Wisby .

</description>
  <guid>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/pressinbjudan-almedalen-valet-2014-ett-vaardval-654330?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</guid>
  <link>http://www.mynewsdesk.com/se/pressroom/pfizer/pressrelease/view/pressinbjudan-almedalen-valet-2014-ett-vaardval-654330?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=pressrelease</link>
  <dc:creator>Pfizer AB</dc:creator>
</item>
  </channel>
</rss>

